Skip to content

AstraZeneca to Help Develop Imperial’s New RNA Technology

Updated on
  • British partners to focus on possible next generation approach
  • Astra, Imperial researchers will target range of diseases

Follow us at @BloombergUK for the latest news and analysis.

AstraZeneca Plc and an Imperial College London startup will work together to develop a potential next generation of messenger RNA technology to fight cancer and other diseases, seeing opportunities well beyond Covid-19.